

02-05-04

1624

Attorney Docket No. 5698.210-US
Jeppesen et al.
Serial No. 10/076,574 Filed February 8, 2002
Express Mail Label No. EV409532869 US

Attorney Docket No.: 5698.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 10/076,574

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthorn Ngo

For: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ Activators (As Amended)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

FEB 10 2004

TECH CENTER 1600/2000

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment/Response

is being deposited with the United States Postal Service as Express Mail Label No. EV 409532869
US in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 4, 2004

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)

Attorney Docket No. 5698.210-US
Jeppesen et al.
Serial No. 10/076,574 Filed February 8, 2002
Express Mail Label No. EV409532869 US



Attorney Docket No.: 5698.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 10/076,574

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

Confirmation No.: 2406

For: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ Activators (as amended)

AMENDMENT/RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
FEB 10 2004
TECH CENTER 1600/28

Sir:

This amendment is submitted in response to the first Office Action on the merits mailed November 6, 2003, having a shortened statutory period for reply set to expire February 6, 2004, subject to extensions of time under the provisions of 37 CFR §1.136(a).

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this amendment/response, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk Pharmaceuticals, Inc., for any such required fee.

The Examiner states in the Office Action Summary that claims numbered 1, 2, 7, 17, 45-47, and 53-55 are pending in the application; claims numbered 1, 2, 7, 17, 46, 47, and 53-55 are rejected; and claim number 45 is objected to.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application, with current amendments noted.

Claim number 54 has been amended. Claim number 53 has been cancelled. No new matter has been introduced by this amendment.